The Raynaud syndrome is a medical condition which is also known as Raynaud’s phenomenon. A human body with this disease experience a pain in the extremities as this the spasm of arteries causes episodes of reduced the flow of blood. Usually, the fingers and less commonly the toes are included. Moreover, there are two main types of this disease such as the primary Raynaud’s and the secondary Raynaud’s. For instance, it is expected that this disease affects 5 to 10 percent of the Americans, but only 1 in 10 seek treatment. Whereas, the females are an assessed nine times more likely to be affected than males. Hence, the key players of this market are playing an important role by doing effective advancement in the technology, development and innovations in the old processing units and introduction of new healthcare institutions leads to the effective growth during the forecasted period with the more proficiency in the cure.
According to the report analysis, ‘Raynauds Disease Global Clinical Trials Review, H1, 2018’ it is states that there are several key players and health organizations which are recently functioning in this market more effectively for dominating the handsome amount of market share by adopting the effective techniques of doing treatment with the effective technology includes MediQuest Therapeutics, Inc., Orion Corporation, Johnson & Johnson, Covis Pharmaceuticals Inc, Apricus Biosciences Inc, Pfizer Inc, Otsuka Holdings Co Ltd, Forenap Pharma E.U.R.L., Charles River Laboratories International Inc, Allergan Plc, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA’s Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania, National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, and several others. Not only has this, for the effective treatment of this more and more innovated and developed laboratories are introduced with the more developed instruments for doing test related to the cure of this disease.
On the basis of geography, with the effective instrument of treatment and high prevalence of the disease the market of this is spread around the globe more actively which include Europe, Asia Pacific region, North America, Central and South America, Middle East and Africa and Rest of the globe. In addition, both the forms of this disease is frequent in the cold climate. When exposed to cold climate or temperatures, the supply of blood to the toes or fingers, and in some cases the noes or earlobes, is markedly decreased; the skin turns pale or white and becomes cold and numb.
Although, there is no proper treatment for this, but there are ways to maintain the symptoms. For slight forms of this, wrapping the exposed the skin before leaving the house can support and beneficial. If an attack happens, saturating the affected parts in warm, not hot, water can improve symptoms and protect them from worsening. Furthermore, it is expected that the market of Raynaud disease will increase more effectively across the globe over the recent few years with the effective investment by the new investors in the technology of treatment.
To know more, click on the link below:-
Ankur Gupta, Head Marketing & Communications